Earnings Call · Q2 FY2025·2025-08-20

Q2 25EPS -100.00%*·Rev n/aQ1 25EPS +35.85%·Rev n/aQ4 24EPS -100.00%*·Rev n/aQ3 24EPS +77.27%·Rev n/a⚠ consensus missing

NRX Pharmaceuticals, Inc. NRXP

Matthew Patrick Duffy — Chief Business Officer

Jonathan C. Javitt — Chief Executive Officer

Michael S. Abrams — Chief Financial Officer

−9.2%1d on move date−8.7% vs SPY3d−8.3%5d−2.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NRXP calls or request research access.

More NRXP calls Browse calls Request research access